Type to search

Ultomiris Met Primary Endpoint in CHAMPION-NMOSD Phase III Trial in Adults with Neuromyelitis Optica Spectrum Disorder | Pharmtech Focus
Neurimmune Enters into a Collaboration and License Agreement with AstraZeneca to Develop and Commercialize NI006 | Pharmtech Focus